1,770 results on '"Günthard, Huldrych F"'
Search Results
2. 2022 update of the drug resistance mutations in HIV-1.
- Author
-
Wensing, Annemarie M, Calvez, Vincent, Ceccherini-Silberstein, Francesca, Charpentier, Charlotte, Günthard, Huldrych F, Paredes, Roger, Shafer, Robert W, and Richman, Douglas D
- Subjects
Humans ,HIV-1 ,HIV Infections ,Anti-HIV Agents ,Drug Resistance ,Viral ,Mutation ,HIV/AIDS ,Antimicrobial Resistance ,Evaluation of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being - Abstract
The 2022 edition of the IAS-USA drug resistance mutations list updates the Figure last published in September 2019. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners to identify key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.
- Published
- 2022
3. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
- Author
-
Barkauskas, Christina, Mylonakis, Eleftherios, Poulakou, Garyfallia, Young, Barnaby E, Vock, David M, Siegel, Lianne, Engen, Nicole, Grandits, Greg, Mosaly, Nilima R, Vekstein, Andrew M, Rogers, Ralph, Shehadeh, Fadi, Kaczynski, Matthew, Mylona, Evangelia K, Syrigos, Konstantinos N, Rapti, Vasiliki, Lye, David C, Hui, Diong Shiau, Leither, Lindsay, Knowlton, Kirk U, Jain, Mamta K, Marines-Price, Rubria, Osuji, Alice, Overcash, J Scott, Kalomenidis, Ioannis, Barmparessou, Zafeiria, Waters, Michael, Zepeda, Karla, Chen, Peter, Torbati, Sam, Kiweewa, Francis, Sebudde, Nicholus, Almasri, Eyad, Hughes, Alyssa, Bhagani, Sanjay R, Rodger, Alison, Sandkovsky, Uriel, Gottlieb, Robert L, Nnakelu, Eriobu, Trautner, Barbara, Menon, Vidya, Lutaakome, Joseph, Matthay, Michael, Robinson, Philip, Protopapas, Konstantinos, Koulouris, Nikolaos, Kimuli, Ivan, Baduashvili, Amiran, Braun, Dominique L, Günthard, Huldrych F, Ramachandruni, Srikanth, Kidega, Robert, Kim, Kami, Hatlen, Timothy J, Phillips, Andrew N, Murray, Daniel D, Jensen, Tomas O, Padilla, Maria L, Accardi, Evan X, Shaw-Saliba, Katy, Dewar, Robin L, Teitelbaum, Marc, Natarajan, Ven, Laverdure, Sylvain, Highbarger, Helene C, Rehman, M Tauseef, Vogel, Susan, Vallée, David, Crew, Page, Atri, Negin, Schechner, Adam J, Pett, Sarah, Hudson, Fleur, Badrock, Jonathan, Touloumi, Giota, Brown, Samuel M, Self, Wesley H, North, Crystal M, Ginde, Adit A, Chang, Christina C, Kelleher, Anthony, Nagy-Agren, Stephanie, Vasudeva, Shikha, Looney, David, Nguyen, Hien H, Sánchez, Adriana, Weintrob, Amy C, Grund, Birgit, Sharma, Shweta, Reilly, Cavan S, Paredes, Roger, Bednarska, Agnieszka, Gerry, Norman P, Babiker, Abdel G, Davey, Victoria J, Gelijns, Annetine C, Higgs, Elizabeth S, Kan, Virginia, Matthews, Gail, and Thompson, B Taylor
- Subjects
Clinical Research ,Clinical Trials and Supportive Activities ,Lung ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Adult ,Designed Ankyrin Repeat Proteins ,Double-Blind Method ,Humans ,Recombinant Fusion Proteins ,SARS-CoV-2 ,Treatment Outcome ,COVID-19 Drug Treatment ,ACTIV-3/TICO Study Group ,Clinical Sciences ,Public Health and Health Services - Abstract
BackgroundEnsovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection.ObjectiveTo investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone.DesignDouble-blind, randomized, placebo-controlled, clinical trial. (ClinicalTrials.gov: NCT04501978).SettingMultinational, multicenter trial.ParticipantsAdults hospitalized with COVID-19.InterventionIntravenous ensovibep, 600 mg, or placebo.MeasurementsEnsovibep was assessed for early futility on the basis of pulmonary ordinal scores at day 5. The primary outcome was time to sustained recovery through day 90, defined as 14 consecutive days at home or place of usual residence after hospital discharge. A composite safety outcome that included death, serious adverse events, end-organ disease, and serious infections was assessed through day 90.ResultsAn independent data and safety monitoring board recommended that enrollment be halted for early futility after 485 patients were randomly assigned and received an infusion of ensovibep (n = 247) or placebo (n = 238). The odds ratio (OR) for a more favorable pulmonary outcome in the ensovibep (vs. placebo) group at day 5 was 0.93 (95% CI, 0.67 to 1.30; P = 0.68; OR > 1 would favor ensovibep). The 90-day cumulative incidence of sustained recovery was 82% for ensovibep and 80% for placebo (subhazard ratio [sHR], 1.06 [CI, 0.88 to 1.28]; sHR > 1 would favor ensovibep). The primary composite safety outcome at day 90 occurred in 78 ensovibep participants (32%) and 70 placebo participants (29%) (HR, 1.07 [CI, 0.77 to 1.47]; HR
- Published
- 2022
4. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
- Author
-
Group, ACTIV-3 Therapeutics for Inpatients with COVID-19 Study, Self, Wesley H, Sandkovsky, Uriel, Reilly, Cavan S, Vock, David M, Gottlieb, Robert L, Mack, Michael, Golden, Kevin, Dishner, Emma, Vekstein, Andrew, Ko, Emily R, Der, Tatyana, Franzone, John, Almasri, Eyad, Fayed, Mohamed, Filbin, Michael R, Hibbert, Kathryn A, Rice, Todd W, Casey, Jonathan D, Hayanga, J Awori, Badhwar, Vinay, Leshnower, Bradley G, Sharifpour, Milad, Knowlton, Kirk U, Peltan, Ithan D, Bakowska, Elizieta, Kowalska, Justyna, Bowdish, Michael E, Sturek, Jeffrey M, Rogers, Angela J, Files, D Clark, Mosier, Jarrod M, Gong, Michelle N, Douin, David J, Hite, R Duncan, Trautner, Barbara W, Jain, Mamta K, Gardner, Edward M, Khan, Akram, Jensen, Jens-Ulrik, Matthay, Michael A, Ginde, Adit A, Brown, Samuel M, Higgs, Elizabeth S, Pett, Sarah, Weintrob, Amy C, Chang, Christina C, Murrary, Daniel D, Günthard, Huldrych F, Moquete, Ellen, Grandits, Greg, Engen, Nicole, Grund, Birgit, Sharma, Shweta, Cao, Huyen, Gupta, Rajesh, Osei, Suzette, Margolis, David, Zhu, Qing, Polizzotto, Mark N, Babiker, Abdel G, Davey, Victoria J, Kan, Virginia, Thompson, B Taylor, Gelijns, Annetine C, Neaton, James D, Lane, H Clifford, Jundgren, Jens D, Tierney, John, Barrett, Kevin, Herpin, Betsey R, Smolskis, Mary C, Voge, Susan E, McNay, Laura A, Cahill, Kelly, Crew, Page, Kirchoff, Matthew, Sardana, Ratna, Raim, Sharon Segal, Chiu, Joseph, Hensley, Lisa, Lorenzo, Josua, Mock, Rebecca, Shaw-Saliba, Katy, Zuckerman, Judith, Adam, Stacey J, Currier, Judy, Read, Sarah, Hughes, Eric, Amos, Laura, Carlsen, Amy, Carter, Anita, Davis, Bionca, Denning, Eileen, DuChene, Alain, Harrison, Merrie, Kaiser, Payton, Koopmeiners, Joseph, Meger, Sue, and Murray, Thomas
- Subjects
Clinical Trials and Supportive Activities ,Lung ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Antibodies ,Monoclonal ,Antibodies ,Monoclonal ,Humanized ,Antibodies ,Neutralizing ,Double-Blind Method ,Female ,Humans ,Male ,Middle Aged ,SARS-CoV-2 ,Treatment Outcome ,COVID-19 Drug Treatment ,ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group ,Clinical Sciences ,Medical Microbiology ,Public Health and Health Services ,Microbiology - Abstract
BackgroundWe aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.MethodsIn this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978.FindingsBetween Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50-72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74-1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67-1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74-1·58]; BRII-196 plus BRII-198 1·00 [0·68-1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91-1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88-1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90.InterpretationNeither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19.FundingUS National Institutes of Health and Operation Warp Speed.
- Published
- 2022
5. Assessing immunogenicity barriers of the HIV-1 envelope trimer
- Author
-
Maliqi, Liridona, Friedrich, Nikolas, Glögl, Matthias, Schmutz, Stefan, Schmidt, Daniel, Rusert, Peter, Schanz, Merle, Zaheri, Maryam, Pasin, Chloé, Niklaus, Cyrille, Foulkes, Caio, Reinberg, Thomas, Dreier, Birgit, Abela, Irene, Peterhoff, David, Hauser, Alexandra, Kouyos, Roger D., Günthard, Huldrych F., van Gils, Marit J., Sanders, Rogier W., Wagner, Ralf, Plückthun, Andreas, and Trkola, Alexandra
- Published
- 2023
- Full Text
- View/download PDF
6. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
- Author
-
Abela, I, Aebi-Popp, K, Anagnostopoulos, A, Battegay, M, Bernasconi, E, Braun, DL, Bucher, HC, Calmy, A, Cavassini, M, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Günthard, HF, Hachfeld, A, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Huber, M, Jackson-Perry, D, Kahlert, CR, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, RD, Kovari, H, Kusejko, K, Labhardt, N, Leuzinger, K, Martinez de Tejada, B, Marzolini, C, Metzner, KJ, Müller, N, Nemeth, J, Nicca, D, Notter, J, Paioni, P, Pantaleo, G, Perreau, M, Rauch, A, Salazar-Vizcaya, L, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Wandeler, G, Weisser, M, Yerly, S, Thoueille, Paul, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva, Munting, Aline, Cavassini, Matthias, Braun, Dominique, Günthard, Huldrych F., Kusejko, Katharina, Surial, Bernard, Furrer, Hansjakob, Rauch, Andri, Rougemont, Mathieu, Ustero, Pilar, Calmy, Alexandra, Stöckle, Marcel, Marzolini, Catia, Di Benedetto, Caroline, Bernasconi, Enos, Schmid, Patrick, Piso, Rein Jan, Andre, Pascal, Girardin, François R., Guidi, Monia, Buclin, Thierry, and Decosterd, Laurent A.
- Published
- 2024
- Full Text
- View/download PDF
7. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes
- Author
-
Mocroft, Amanda, Pelchen-Matthews, Annegret, Hoy, Jennifer, Llibre, Josep M., Neesgaard, Bastian, Jaschinski, Nadine, Domingo, Pere, Rasmussen, Line Dahlerup, Günthard, Huldrych F., Surial, Bernard, Öllinger, Angela, Knappik, Michael, de Wit, Stephane, Wit, Ferdinand, Mussini, Cristina, Vehreschild, Joerg, Monforte, Antonella D’Arminio, Sonnerborg, Anders, Castagna, Antonella, Anne, Alain Volny, Vannappagari, Vani, Cohen, Cal, Greaves, Wayne, Wasmuth, Jan C., Spagnuolo, Vincenzo, and Ryom, Lene
- Published
- 2024
- Full Text
- View/download PDF
8. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1
- Author
-
Chammartin, Frédérique, Griessbach, Alexandra, Kusejko, Katharina, Audigé, Annette, Epp, Selina, Stoeckle, Marcel P., Eichenberger, Anna L., Amstutz, Alain, Schoenenberger, Christof M., Hasse, Barbara, Braun, Dominique L., Rauch, Andri, Trkola, Alexandra, Briel, Matthias, Bucher, Heiner C., Günthard, Huldrych F., Speich, Benjamin, and Abela, Irene A.
- Published
- 2024
- Full Text
- View/download PDF
9. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis
- Author
-
Loosli, Tom, Hossmann, Stefanie, Ingle, Suzanne M, Okhai, Hajra, Kusejko, Katharina, Mouton, Johannes, Bellecave, Pantxika, van Sighem, Ard, Stecher, Melanie, d'Arminio Monforte, Antonella, Gill, M John, Sabin, Caroline A, Maartens, Gary, Günthard, Huldrych F, Sterne, Jonathan A C, Lessells, Richard, Egger, Matthias, and Kouyos, Roger D
- Published
- 2023
- Full Text
- View/download PDF
10. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- Author
-
Saag, Michael S, Gandhi, Rajesh T, Hoy, Jennifer F, Landovitz, Raphael J, Thompson, Melanie A, Sax, Paul E, Smith, Davey M, Benson, Constance A, Buchbinder, Susan P, del Rio, Carlos, Eron, Joseph J, Fätkenheuer, Gerd, Günthard, Huldrych F, Molina, Jean-Michel, Jacobsen, Donna M, and Volberding, Paul A
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Clinical Sciences ,Medical Microbiology ,Patient Safety ,Clinical Research ,Infectious Diseases ,HIV/AIDS ,Sexually Transmitted Infections ,Prevention ,Clinical Trials and Supportive Activities ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,AIDS-Related Opportunistic Infections ,Age Factors ,Anti-Retroviral Agents ,Betacoronavirus ,COVID-19 ,Comorbidity ,Coronavirus Infections ,Drug Administration Schedule ,Drug Costs ,Drug Resistance ,Viral ,Drug Substitution ,Drug Therapy ,Combination ,Female ,HIV Infections ,Humans ,International Agencies ,Male ,Pandemics ,Pneumonia ,Viral ,Polypharmacy ,Pre-Exposure Prophylaxis ,Pregnancy ,Pregnancy Complications ,Infectious ,RNA ,Viral ,SARS-CoV-2 ,Societies ,Medical ,United States ,Viral Load ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceData on the use of antiretroviral drugs, including new drugs and formulations, for the treatment and prevention of HIV infection continue to guide optimal practices.ObjectiveTo evaluate new data and incorporate them into current recommendations for initiating HIV therapy, monitoring individuals starting on therapy, changing regimens, preventing HIV infection for those at risk, and special considerations for older people with HIV.Evidence reviewNew evidence was collected since the previous International Antiviral (formerly AIDS) Society-USA recommendations in 2018, including data published or presented at peer-reviewed scientific conferences through August 22, 2020. A volunteer panel of 15 experts in HIV research and patient care considered these data and updated previous recommendations.FindingsFrom 5316 citations about antiretroviral drugs identified, 549 were included to form the evidence basis for these recommendations. Antiretroviral therapy is recommended as soon as possible for all individuals with HIV who have detectable viremia. Most patients can start with a 3-drug regimen or now a 2-drug regimen, which includes an integrase strand transfer inhibitor. Effective options are available for patients who may be pregnant, those who have specific clinical conditions, such as kidney, liver, or cardiovascular disease, those who have opportunistic diseases, or those who have health care access issues. Recommended for the first time, a long-acting antiretroviral regimen injected once every 4 weeks for treatment or every 8 weeks pending approval by regulatory bodies and availability. For individuals at risk for HIV, preexposure prophylaxis with an oral regimen is recommended or, pending approval by regulatory bodies and availability, with a long-acting injection given every 8 weeks. Monitoring before and during therapy for effectiveness and safety is recommended. Switching therapy for virological failure is relatively rare at this time, and the recommendations for switching therapies for convenience and for other reasons are included. With the survival benefits provided by therapy, recommendations are made for older individuals with HIV. The current coronavirus disease 2019 pandemic poses particular challenges for HIV research, care, and efforts to end the HIV epidemic.Conclusion and relevanceAdvances in HIV prevention and management with antiretroviral drugs continue to improve clinical care and outcomes among individuals at risk for and with HIV.
- Published
- 2020
11. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection
- Author
-
Abela, I., Aebi-Popp, K., Anagnostopoulos, A., Battegay, M., Bernasconi, E., Braun, D.L., Bucher, H.C., Calmy, A., Cavassini, M., Ciuffi, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, C.A., Günthard, H.F., Hachfeld, A., Haerry, D., Hasse, B., Hirsch, H.H., Hoffmann, M., Hösli, I., Huber, M., Jackson-Perry, D., Kahlert, C.R., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, R.D., Kovari, H., Kusejko, K., Labhardt, N., Leuzinger, K., de Tejada B, Martinez, Marzolini, C., Metzner, K.J., Müller, N., Nemeth, J., Nicca, D., Notter, J., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Salazar-Vizcaya, L., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Wandeler, G., Weisser, M., Yerly, S., van der Valk, M., Geerlings, S.E., Goorhuis, A., Harris, V.C., Hovius, J.W., Lempkes, B., Nellen, F.J.B., van der Poll, T., Prins, J.M., Spoorenberg, V., van Vugt, M., Wiersinga, W.J., Wit, F.W.M.N., Bruins, C., van Eden, J., Hylkema-van den Bout, I.J., van Hes, A.M.H., Pijnappel, F.J.J., Smalhout, S.Y., Weijsenfeld, A.M., Back, N.K.T., Berkhout, B., Cornelissen, M.T.E., van Houdt, R., Jonges, M., Jurriaans, S., Schinkel, C.J., Wolthers, K.C., Zaaijer, H.L., Peters, E.J.G., van Agtmael, M.A., Autar, R.S., Bomers, M., Sigaloff, K.C.E., Heitmuller, M., Laan, L.M., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., van Arkel, A., Stohr, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., de Munnik, E.S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., van Eeden, A., Hoornenborg, E., Nellen, J., Alers, W., Elsenburg, L.J.M., Nobel, H., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., de Kruijf-van de Wiel, B.A.F.M., Adams, A., Rijkevoorsel, M. Pawels-van, Buiting, A.G.M., Murck, J.L., Rokx, C., Anas, A.A., Bax, H.I., van Gorp, E.C.M., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Schurink, C.A.M., Slobbe, L., de Vries-Sluijs, T.E.M.S., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., van Kampen, J.J.A., Koopmans, M.P.G., Rahamat-Langendoen, J.C., Branger, J., Douma, R.A., Cents-Bosma, A.S., Duijf-van de Ven, C.J.H.M., Schippers, E.F., van Nieuwkoop, C., Geilings, J., van Winden, S., van der Hut, G., van Burgel, N.D., Leyten, E.M.S., Gelinck, L.B.S., Mollema, F., Wildenbeest, G.S., Nguyen, T., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., van Hulzen, A.G.W., Kraan, S., Kruiper, M.S.M., van der Bliek, G.L., Bor, P.C.J., Debast, S.B., Wagenvoort, G.H.J., Roukens, A.H.E., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Scheper, H., Dorama, W., van Holten, N., Claas, E.C.J., Wessels, E., Hollander, J.G. den, El Moussaoui, R., Pogany, K., Brouwer, C.J., Heida-Peters, D., Mulder, E., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., Pontesilli, O., van Tienen, C., Lowe, S.H., Lashof, A.M.L. Oude, Posthouwer, D., van Wolfswinkel, M.E., Ackens, R.P., Burgers, K., Elasri, M., Schippers, J., Havenith, T.R.A., van Loo, M., van Vonderen, M.G.A., Kampschreur, L.M., van Broekhuizen, M.C., S, Faber, Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Wagenaar, J., Ruiter-Pronk, D., van Truijen-Oud, F.A., Stuart, J.W.T. Cohen, Hoogewerf, M., Rozemeijer, W., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Veenstra, J., Vrouenraets, S.M.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Knapen, M., Kok, M., van der Meché, I.B., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van de Laar, T.J.W., van Crevel, R., van Aerde, K., Dofferhoff, A.S.M., Henriet, S.S.V., Hofstede, H.J.M. ter, Hoogerwerf, J., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., McCall, M., Burger, D., Gisolf, E.H., Claassen, M., Hassing, R.J., Beest, G. ter, van Bentum, P.H.M., Gelling, M., Neijland, Y., Swanink, C.M.A., Velderman, M. Klein, van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Kalpoe, J.S., Wagemakers, A., Vahidnia, A., Lauw, F.N., Verhagen, D.W.M., van Wijk, M., Bierman, W.F.W., Bakker, M., van Bentum, R.A., van den Boomgaard, M.A., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Schenk, H.M., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., de Jonge, H., Maerman, M.M.M., de Weerd, D.A., van Eije, K.J., Knoester, M., van Leer-Buter, C.C., Niesters, H.G.M., T.Mudrikova, Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Hensgens, M.P.M., Oosterheert, J.J., Schadd, E.M., Verbon, A., van Welzen, B.J., Berends, H., Santen, B.M.G. Griffioen-van, de Kroon, I., Lunel, F.M. Verduyn, Wensing, A.M.J., Zaheri, S., Boyd, A.C., Bezemer, D.O., van Sighem, A.I., Smit, C., Hillebregt, M.M.J., Woudstra, T.J., Rutkens, T., Bergsma, D., Brétin, N.M., Lelivelt, K.J., van de Sande, L., van der Vliet, K.M. Visser.S.T., Paling, F., de Groot-Berndsen, L.G.M., van den Akker, M., Alexander, R., Bakker, Y., El Berkaoui, A., Bezemer-Goedhart, M., Djoechro, E.A., Groters, M., Koster, L.E., Lodewijk, C.R.E., Lucas, E.G.A., Munjishvili, L., Peeck, B.M., Ree, C.M.J., Regtop, R., van Rijk, A.F., Ruijs-Tiggelman, Y.M.C., Schnörr, P.P., Schoorl, M.J.C., Tuijn, E.M., Veenenberg, D.P., Witte, E.C.M., Bretin, N.M., Karpov, I., Losso, M., Lundgren, J., Rockstroh, J., Aho, I., Rasmussen, L.D., Novak, P., Pradier, C., Chkhartishvili, N., Matulionyte, R., Oprea, C., Kowalska, J.D., Begovac, J., Miró, J.M., Guaraldi, G., Paredes, R., Peters, L., Larsen, J.F., Neesgaard, B., Jaschinski, N., Fursa, O., Raben, D., Kristensen, D., Fischer, A.H., Jensen, S.K., Elsing, T.W., Gardizi, M., Mocroft, A., Phillips, A., Reekie, J., Cozzi-Lepri, A., Pelchen-Matthews, A., Roen, A., Tusch, E.S., Bannister, W., Bellecave, P., Blanco, P., Bonnet, F., Bouchet, S., Breilh, D., Cazanave, C., Desjardin, S., Gaborieau, V., Gimbert, A., Hessamfar, M., Lacaze-Buzy, L., Lacoste, D., Lafon, M.E., Lazaro, E., Leleux, O., Le Marec, F., Le Moal, G., Malvy, D., Marchand, L., Mercié, P., Neau, D., Pellegrin, I., Perrier, A., Petrov-Sanchez, V., Vareil, M.O., Wittkop, L., Bernard, N., Chaussade, D. Bronnimann H., Dondia, D., Duffau, P., Faure, I., Morlat, P., Mériglier, E., Paccalin, F., Riebero, E., Rivoisy, C., Vandenhende, M.A., Barthod, L., Dauchy, F.A., Desclaux, A., Ducours, M., Dutronc, H., Duvignaud, A., Leitao, J., Lescure, M., Nguyen, D., Pistone, T., Puges, M., Wirth, G., Courtault, C., Camou, F., Greib, C., Pellegrin, J.L., Rivière, E., Viallard, J.F., Imbert, Y., Thierry-Mieg, M., Rispal, P., Caubet, O., Ferrand, H., Tchamgoué, S., Farbos, S., Wille, H., Andre, K., Caunegre, L., Gerard, Y., Osorio-Perez, F., Chossat, I., Iles, G., Labasse-Depis, M., Lacassin, F., Barret, A., Castan, B., Koffi, J., Rouanes, N., Saunier, A., Zabbe, J.B., Dumondin, G., Beraud, G., Catroux, M., Garcia, M., Giraud, V., Martellosio, J.P., Roblot, F., Pasdeloup, T., Riché, A., Grosset, M., Males, S., Bell, C. Ngo, Carpentier, C., Bellecave, Virology P., Tumiotto, C., Miremeont-Salamé, G., Arma, D., Arnou, G., Blaizeau, M.J., Camps, P., Decoin, M., Delveaux, S., Diarra, F., Gabrea, L., Lawson-Ayayi, S., Lenaud, E., Plainchamps, D., Pougetoux, A., Uwamaliya, B., Zara, K., Conte, V., Gapillout, M., Surial, Bernard, Ramírez Mena, Adrià, Roumet, Marie, Limacher, Andreas, Smit, Colette, Leleux, Olivier, Mocroft, Amanda, van der Valk, Marc, Bonnet, Fabrice, Peters, Lars, Rockstroh, Jürgen K., Günthard, Huldrych F., Berzigotti, Annalisa, Rauch, Andri, and Wandeler, Gilles
- Published
- 2023
- Full Text
- View/download PDF
12. Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV
- Author
-
Roen, Ashley O, primary, Peters, Lars, additional, Wandeler, Gilles, additional, van der Valk, Marc, additional, Zangerle, Robert, additional, Günthard, Huldrych F, additional, Wit, Ferdinand, additional, Mussini, Cristina, additional, De Wit, Stéphane, additional, d’Arminio Monforte, Antonella, additional, Vehreschild, Jörg Janne, additional, Castagna, Antonella, additional, Jaschinski, Nadine, additional, Vannappagari, Vani, additional, Chen, Linda, additional, Tallada, Joan, additional, C’mar, John, additional, Mocroft, Amanda, additional, and Ryom, Lene, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial
- Author
-
Hepprich, Matthias, Mudry, Jonathan M., Gregoriano, Claudia, Jornayvaz, Francois R., Carballo, Sebastian, Wojtusciszyn, Anne, Bart, Pierre-Alexandre, Chiche, Jean-Daniel, Fischli, Stefan, Baumgartner, Thomas, Cavelti-Weder, Claudia, Braun, Dominique L., Günthard, Huldrych F., Beuschlein, Felix, Conen, Anna, West, Emily, Isenring, Egon, Zechmann, Stefan, Bucklar, Gabriela, Aubry, Yoann, Dey, Ludovic, Müller, Beat, Hunziker, Patrick, Schütz, Philipp, Cattaneo, Marco, and Donath, Marc Y.
- Published
- 2022
- Full Text
- View/download PDF
14. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
- Author
-
Ginde, Adit A., Paredes, Roger, Murray, Thomas A., Engen, Nicole, Grandits, Greg, Vekstein, Andrew, Ivey, Noel, Mourad, Ahmad, Sandkovsky, Uriel, Gottlieb, Robert L., Berhe, Mezgebe, Jain, Mamta K., Marines-Price, Rubria, Agbor Agbor, Barbine Tchamba, Mateu, Lourdes, España-Cueto, Sergio, Lladós, Gemma, Mylonakis, Eleftherios, Rogers, Ralph, Shehadeh, Fadi, Filbin, Michael R., Hibbert, Kathryn A., Kim, Kami, Tran, Thanh, Morris, Peter E., Cassity, Evan P., Trautner, Barbara, Pandit, Lavannya M., Knowlton, Kirk U., Leither, Lindsay, Matthay, Michael A., Rogers, Angela J., Drake, Wonder, Jones, Beatrice, Poulakou, Garyfallia, Syrigos, Konstantinos N., Fernández-Cruz, Eduardo, Natale, Marisa Di, Almasri, Eyad, Balerdi-Sarasola, Leire, Bhagani, Sanjay R., Boyle, Katherine L., Casey, Jonathan D., Chen, Peter, Douin, David J., Files, D. Clark, Günthard, Huldrych F., Hite, R. Duncan, Hyzy, Robert C., Khan, Akram, Kibirige, Moses, Kidega, Robert, Kiweewa, Francis, Jensen, Jens-Ulrik, Leshnower, Bradley G., Lutaakome, Joseph K., Manian, Prasad, Menon, Vidya, Morales-Rull, Jose Luis, O'Mahony, D. Shane, Overcash, J. Scott, Ramachandruni, Srikant, Steingrub, Jay S., Taha, Hassan S., Waters, Michael, Young, Barnaby E., Phillips, Andrew N., Murray, Daniel D., Jensen, Tomas O., Padilla, Maria L., Sahner, David, Shaw-Saliba, Katy, Dewar, Robin L., Teitelbaum, Marc, Natarajan, Ven, Rehman, M. Tauseef, Pett, Sarah, Hudson, Fleur, Touloumi, Giota, Brown, Samuel M., Self, Wesley H., Chang, Christina C., Sánchez, Adriana, Weintrob, Amy C., Hatlen, Timothy, Grund, Birgit, Sharma, Shweta, Reilly, Cavan S., Garbes, Pedro, Esser, Mark T., Templeton, Alison, Babiker, Abdel G., Davey, Victoria J., Gelijns, Annetine C., Higgs, Elizabeth S., Kan, Virginia, Matthews, Gail, Thompson, B. Taylor, Neaton, James D., Lane, H. Clifford, and Lundgren, Jens D.
- Published
- 2022
- Full Text
- View/download PDF
15. 2019 update of the drug resistance mutations in HIV-1.
- Author
-
Wensing, Annemarie M, Calvez, Vincent, Ceccherini-Silberstein, Francesca, Charpentier, Charlotte, Günthard, Huldrych F, Paredes, Roger, Shafer, Robert W, and Richman, Douglas D
- Subjects
Humans ,HIV-1 ,HIV Infections ,Reverse Transcriptase Inhibitors ,HIV Protease Inhibitors ,Anti-HIV Agents ,Amino Acid Substitution ,Drug Resistance ,Viral ,Mutation ,Genes ,Viral ,United States ,Drug Resistance ,Viral ,Genes - Abstract
The 2019 edition of the IAS-USA drug resistance mutations list updates the Figure last published in January 2017. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.
- Published
- 2019
16. Reply to Ambrosioni et al.
- Author
-
Günthard, Huldrych F, Calvez, Vincent, Paredes, Roger, Pillay, Deenan, Shafer, Robert W, Wensing, Annemarie M, Jacobsen, Donna M, and Richman, Douglas D
- Subjects
Antiviral Agents ,Drug Resistance ,HIV ,HIV Infections ,Humans ,Societies ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Published
- 2019
17. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel
- Author
-
Günthard, Huldrych F, Calvez, Vincent, Paredes, Roger, Pillay, Deenan, Shafer, Robert W, Wensing, Annemarie M, Jacobsen, Donna M, and Richman, Douglas D
- Subjects
Clinical Research ,Antimicrobial Resistance ,HIV/AIDS ,Infectious Diseases ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Anti-HIV Agents ,Developing Countries ,Drug Resistance ,Viral ,HIV Infections ,HIV-1 ,Humans ,Internationality ,Societies ,Scientific ,United States ,HIV ,antiretroviral therapy ,drug resistance ,therapeutic failure ,resource-rich ,low and middle income countries ,HIV-1 subtype ,genotypic drug resistance ,sanger sequencing ,next generation sequencing ,Biological Sciences ,Medical and Health Sciences ,Microbiology - Abstract
BackgroundContemporary antiretroviral therapies (ART) and management strategies have diminished both human immunodeficiency virus (HIV) treatment failure and the acquired resistance to drugs in resource-rich regions, but transmission of drug-resistant viruses has not similarly decreased. In low- and middle-income regions, ART roll-out has improved outcomes, but has resulted in increasing acquired and transmitted resistances. Our objective was to review resistance to ART drugs and methods to detect it, and to provide updated recommendations for testing and monitoring for drug resistance in HIV-infected individuals.MethodsA volunteer panel of experts appointed by the International Antiviral (formerly AIDS) Society-USA reviewed relevant peer-reviewed data that were published or presented at scientific conferences. Recommendations were rated according to the strength of the recommendation and quality of the evidence, and reached by full panel consensus.ResultsResistance testing remains a cornerstone of ART. It is recommended in newly-diagnosed individuals and in patients in whom ART has failed. Testing for transmitted integrase strand-transfer inhibitor resistance is currently not recommended, but this may change as more resistance emerges with widespread use. Sanger-based and next-generation sequencing approaches are each suited for genotypic testing. Testing for minority variants harboring drug resistance may only be considered if treatments depend on a first-generation nonnucleoside analogue reverse transcriptase inhibitor. Different HIV-1 subtypes do not need special considerations regarding resistance testing.ConclusionsTesting for HIV drug resistance in drug-naive individuals and in patients in whom antiretroviral drugs are failing, and the appreciation of the role of testing, are crucial to the prevention and management of failure of ART.
- Published
- 2019
18. Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment-Reply.
- Author
-
Saag, Michael S, Günthard, Huldrych F, and Smith, Davey M
- Subjects
Anti-HIV Agents ,Drug Resistance ,Viral ,Genotype ,HIV ,HIV Infections ,Microbial Sensitivity Tests ,Mutation ,Medical and Health Sciences ,General & Internal Medicine - Published
- 2018
19. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium
- Author
-
Neesgaard, Bastian, Greenberg, Lauren, Miró, Jose M, Grabmeier-Pfistershammer, Katharina, Wandeler, Gilles, Smith, Colette, De Wit, Stéphane, Wit, Ferdinand, Pelchen-Matthews, Annegret, Mussini, Cristina, Castagna, Antonella, Pradier, Christian, d'Arminio Monforte, Antonella, Vehreschild, Jörg J, Sönnerborg, Anders, Anne, Alain V, Carr, Andrew, Bansi-Matharu, Loveleen, Lundgren, Jens D, Garges, Harmony, Rogatto, Felipe, Zangerle, Robert, Günthard, Huldrych F, Rasmussen, Line D, Necsoi, Coca, van der Valk, Marc, Menozzi, Marianna, Muccini, Camilla, Peters, Lars, Mocroft, Amanda, and Ryom, Lene
- Published
- 2022
- Full Text
- View/download PDF
20. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
- Author
-
Self, Wesley H., Sandkovsky, Uriel, Reilly, Cavan S., Vock, David M., Gottlieb, Robert L., Mack, Michael, Golden, Kevin, Dishner, Emma, Vekstein, Andrew, Ko, Emily R., Der, Tatyana, Franzone, John, Almasri, Eyad, Fayed, Mohamed, Filbin, Michael R., Hibbert, Kathryn A., Rice, Todd W., Casey, Jonathan D., Hayanga, J. Awori, Badhwar, Vinay, Leshnower, Bradley G., Sharifpour, Milad, Knowlton, Kirk U., Peltan, Ithan D., Bakowska, Elizieta, Kowalska, Justyna, Bowdish, Michael E., Sturek, Jeffrey M., Rogers, Angela J., Files, D. Clark, Mosier, Jarrod M., Gong, Michelle N., Douin, David J., Hite, R. Duncan, Trautner, Barbara W., Jain, Mamta K., Gardner, Edward M., Khan, Akram, Jensen, Jens-Ulrik, Matthay, Michael A., Ginde, Adit A., Brown, Samuel M., Higgs, Elizabeth S., Pett, Sarah, Weintrob, Amy C., Chang, Christina C., Murrary, Daniel D., Günthard, Huldrych F., Moquete, Ellen, Grandits, Greg, Engen, Nicole, Grund, Birgit, Sharma, Shweta, Cao, Huyen, Gupta, Rajesh, Osei, Suzette, Margolis, David, Zhu, Qing, Polizzotto, Mark N., Babiker, Abdel G., Davey, Victoria J., Kan, Virginia, Thompson, B. Taylor, Gelijns, Annetine C., Neaton, James D., Lane, H. Clifford, Jundgren, Jens D., Tierney, John, Barrett, Kevin, Herpin, Betsey R., Smolskis, Mary C., Voge, Susan E., McNay, Laura A., Cahill, Kelly, Crew, Page, Kirchoff, Matthew, Sardana, Ratna, Raim, Sharon Segal, Chiu, Joseph, Hensley, Lisa, Lorenzo, Josua, Mock, Rebecca, Shaw-Saliba, Katy, Zuckerman, Judith, Adam, Stacey J., Currier, Judy, Read, Sarah, Hughes, Eric, Amos, Laura, Carlsen, Amy, Carter, Anita, Davis, Bionca, Denning, Eileen, DuChene, Alain, Harrison, Merrie, Kaiser, Payton, Koopmeiners, Joseph, Meger, Sue, Murray, Thomas, Quan, Kien, Quan, Siu Fun, Thompson, Greg, Walski, Jamie, Wentworth, Deborah, Moskowitz, Alan J., Bagiella, Emilia, O'Sullivan, Karen, Marks, Mary E., Accardi, Evan, Kinzel, Emily, Bedoya, Gabriela, Gupta, Lopa, Overbey, Jessica R., Padillia, Maria L., Santos, Milerva, Gillinov, Marc A., Miller, Marissa A., Taddei-Peters, Wendy C., Fenton, Kathleen, Berhe, Mezgebe, Haley, Clinton, Bettacchi, Christopher, Duhaime, Erin, Ryan, Madison, Burris, Sarah, Jones, Felecia, Villa, Samantha, Want, Samantha, Robert, Raven, Coleman, Tanquinisha, Clariday, Laura, Baker, Rebecca, Hurutado-Rodriguez, Marian, Iram, Nazia, Fresnedo, Michelle, Davis, Allyson, Leonard, Kiara, Ramierez, Noelia, Thammavong, Jon, Duque, Krizia, Turner, Emma, Fisher, Tammy, Robinson, Dianna, Ransom, Desirae, Lusk, Erica, Killian, Aaron, Palacious, Adriana, Solis, Edilia, Jerrow, Janet, Watts, Matthew, Whitacre, Heather, Cothran, Elizabeth, Smith, Peter K., Barkauskas, Christina E., Dreyer, Grace R., Witte, Marie, Mosaly, Nilima, Mourad, Ahmad, Holland, Thomas L., Lane, Kathleen, Bouffler, Andrew, McGowan, Lauren M., Motta, Marry, Tipton, Gregory, Stallings, Ben, Stout, Gennifer, McLendon-Arvik, Beth, Hollister, Beth A., Giangiacomo, Dana M., Sharma, Sunil, Pappers, Brian, McCarthy, Paul, Krupica, Troy, Sarwari, Arif, Reece, Rebecca, Fornaresio, Lisa, Glaze, Chad, Evans, Raquel, Preamble, Katarina, Sutton, Lisa Giblin, Buterbaugh, Sabrina, Bartolo, Elizabeth Berry, Williams, Roger, Bunner, Robin, Bender, William, Miller, Jeffrey, Baio, Kim T., McBride, Mary K., Fielding, Michele, Mathewson, Sonya, Porte, Kristina, Maton, Missy, Ponder, Chari, Haley, Elizabeth, Spainhour, Christine, Rogers, Susan, Tyler, Derrick, Wald-Dickler, Noah, Hutcheon, Douglass, Towfighi, Amytis, Lee, May M., Lewis, Meghan R., Spellberg, Brad, Sher, Linda, Sharma, Aniket, Olds, Anna P., Justino, Chris, Lozano, Edward, Romero, Chris, Leong, Janet, Rodina, Valentina, Possemato, Tammie, Escobar, Jose, Chiu, Charlene, Weissman, Kevin, Barros, Andrew, Enfield, Kyle B., Kadl, Alexandra, Green, China J., Simon, Rachel M., Fox, Ashley, Thornton, Kara, Parrino, Patrick E., Spindel, Stephen, Bansal, Aditya, Baumgarten, Katherine, Hand, Jonathan, Vonderhaar, Derek, Nossaman, Bobby, Laudun, Sylvia, Ames, DeAnna, Broussard, Shane, Hernandez, Nilmo, Isaac, Geralyn, Dinh, Huan, Zheng, Yiling, Tran, Sonny, McDaniel, Hunter, Crovetto, Nicolle, Miller, Leslie, Schelle, Beth, McLean, Sherry, Rothbaum, Howard R., Alvarez, Michael S., Kalan, Shivam P., Germann, Heather H., Hendershot, Jennifer, Maroney, Karen, Herring, Karen, Cook, Sharri, Paul, Pam, Madathil, Ronson J., Rabin, Joseph, Levine, Andrea, Saharia, Kapil, Tabatabai, Ali, Lau, Christine, Gammie, James S., Peguero, Maya-Loren, McKernan, Kimberley, Audette, Matthew, Fleischmann, Emily, Akbari, Freshta, Lee, Maia, Lee, Myounghee, Chi, Andrew, Salehi, Hanna, Pariser, Alan, Nguyen, Phuong Tran, Moore, Jessica, Gee, Adrienne, Vincent, Shelika, Zuckerman, Richard A., Iribarne, Alexander, Metzler, Sara, Shipman, Samantha, Caccia, Taylor, Johnson, Haley, Newton, Crystallee, Parr, Doug, Rodriguez, Vicente, Bokhart, Gordon, Eichman, Sharon M., North, Crystal, Oldmixon, Cathryn, Ringwood, Nancy, Fitzgerald, Laura, Morin, Haley D., Muzikansky, Ariela, Morse, Richard, Brower, Roy G., Reineck, Lora A., Aggarwal, Neil R., Bienstock, Karen, Hou, Peter, Steingrub, Jay, Tidswell, Mark A., Kozikowski, Lori-Ann, Kardos, Cynthia, DeSouza, Leslie, Thornton-Thompson, Sherell, Talmor, Daniel, Shapiro, Nathan, Banner-Goodspeed, Valerie, Boyle, Katherine L., Hayes, Sharon, Jones, Alan E., Galbraith, James, Nandi, Utsav, Peacock, Rebekah K., Parry, Blair Alden, Margolin, Justin D., Brait, Kelsey, Beakes, Caroline, Kangelaris, Kirsten N., Yee, Kimberly J., Ashktorab, Kimia, Jauregui, Alejandra E., Zhuo, Hanjing, Hendey, Gregory, Hubel, Kinsley A., Hughes, Alyssa R., Garcia, Rebekah L., Wilson, Jennifer G., Vojnik, Rosemary, Roque, Jonasel, Perez, Cynthia, Lim, George W., Chang, Steven Y., Beutler, Rebecca, Agarwal, Trisha, Vargas, Julia, Moss, Marc, Baduashvili, Amiran, Chauhan, Lakshmi, Finck, Lani L., Howell, Michelle, Hyzy, Robert C., Park, Pauline K., Nelson, Kristine, McSparron, Jake I., Co, Ivan N., Wang, Bonnie R., Jia, Shijing, Sullins, Barbara, Hanna, Sinan, Olbrich, Norman, Richardson, Lynne D., Nair, Rahul, Offor, Obiageli, Lopez, Brenda, Amosu, Omowunmi, Tzehaie, Hiwet, Terndrup, Thomas E., Wiedemann, Herbert P., Duggal, Abhijit, Thiruchelvam, Nirosshan, Ashok, Kiran, King, Alexander H., Mehkri, Omar, Hudock, Kristin, Kiran, Simra, More, Harshada, Roads, Tammy, Martinkovic, Jamie, Kennedy, Sarah, Robinson, Bryce H., Hough, Catherine L., Krol, Olivia F., Kinjal, Mistry, Mills, Emmanuel, McDougal, Madeline, Deshmukh, Rupali, Chen, Peter, Torbati, Sam S., Matusov, Yuri, Choe, June, Hindoyan, Niree A., Jackman, Susan E., Bayoumi, Emad, Wynter, Timothy, Caudill, Antonina, Pascual, Ethan, Clapham, Gregg J., Herrera, Lisa, Ojukwu, Cristabelle, Mehdikhani, Shaunt, O'Mahony, D. Shane, Nyatsatsang, Sonam T., Wilson, David M., Wallick, Julie A., Miller, Chadwick, Gibbs, Keven W., Flores, Lori S., LaRose, Mary E., Landreth, Leigha D., Morris, Peter E., Sturgill, Jamie L., Cassity, Evan P., Dhar, Sanjay, Montgomery-Yates, Ashley A., Pasha, Sara N., Mayer, Kirby P., Bissel, Brittany, Bledsoe, Joseph, Brown, Samuel, Lanspa, Michael, Leither, Lindsey, Armbruster, Brent P., Montgomery, Quinn, Applegate, Darrin, Kumar, Naresh, Fergus, Melissa, Serezlic, Erna, Imel, Karah, Palmer, Ghazal, Webb, Brandon, Aston, Valerie T., Johnson, Jakea, Gray, Christopher, Hays, Margaret, Roth, Megan, Sánchez, Adriana, Popielski, Laura, Rivasplata, Heather, Turner, Melissa, Vjecha, Michael, Petersen, Tianna, Kamel, Dena, Hansen, Laura, Lucas, Claudia Sanchez, DellaValle, Natalie, Gonzales, Sonia, Scott, James, Wyles, David, Douglas, Ivor, Haukoos, Jason, Kamis, Kevin, Robinson, Caitlin, Baker, Jason V., Frosch, Anne, Goldsmith, Rachael, Jibrell, Hodan, Lo, Melanie, Klaphake, Jonathan, Mackedanz, Shari, Ngo, Linh, Garcia-Myers, Kelly, Markowitz, Norman, Pastor, Erika, Ramesh, Mayur, Brar, Indira, Rivers, Emanuel, Kumar, Princy, Menna, Maximiliano, Biswas, Kousick, Harrington, Cristin, Delp, Alex, Pandit, Lavannya, Hines-Munson, Casey, Van, John, Dillon, Laura, Want, Yiqun, Lichtenberger, Paola, Baracco, Gio, Ramos, Carol, Bjork, Lauren, Sueiro, Melyssa, Tien, Phyllis, Freasier, Heather, Buck, Theresa, Nekach, Hafida, Nagy-Agren, Stephanie, Vasudeva, Shikha, Ochalek, Tracy, Roller, Brentin, Nguyen, Chinh, Mikail, Amani, Raben, Dorthe, Jensen, Tomas O., Aagaard, Bitten, Nielsen, Charlotte B., Krapp, Katharina, Nykjær, Bente Rosdahl, Kanne, Katja Lisa, Grevsen, Anne Louise, Joensen, Zillah Maria, Bruun, Tina, Bojesen, Ane, Woldbye, Frederik, Normand, Nick E., Esmann, Frederik V.L., Clausen, Clara Lundetoft, Hovmand, Nichlas, Pedersen, Karen Brorup, Thorlacius-Ussing, Louise, Tinggaard, Michaela, Høgsberg, Dorthe S., Rastoder, Ema, Kamstrup, Thobias, Bergsøe, Christina Marisa, Østergaard, Lars, Stærke, Nina Breinholt, Johansen, Isik S., Knudtzen, Fredrikke C., Larsen, Lykke, Hertz, Mathias A., Fabricius, Thilde, Helleberg, Marie, Gerstoft, Jan, Jensen, Tomas Østergaard, Lindegaard, Birgitte, Pedersen, Thomas Ingemann, Røge, Birgit Thorup, Løfberg, Sandra Valborg, Hansen, Thomas Michael, Nielsen, Ariella Denize, von Huth, Sebastian Leicht, Nielsen, Henrik, Thisted, Rikke Krog, Podlekareva, Daria, Johnsen, Stine, Andreassen, Helle Frost, Pedersen, Lars, Lindnér, Cecilia Ebba Clara Ellinor, Wiese, Lothar, Knudsen, Lene Surland, Nytofte, Nikolaj Julian Skrøder, Havmøller, Signe Ravn, Paredes, Roger, Exposito, Maria, Fernández-Cruz, Eduardo, Muñoz, José, Arribas, Jose R., Estrada, Vicente, Horcajada, Juan P., Burgos, Joaquin, Morales-Rull, Jose Luis, Braun, Dominique L., West, Emily, M'Rabeth-Bensalah, Khadija, Eichinger, Mareile L., Grüttner-Durmaz, Manuela, Grube, Christina, Zink, Veronika, Horban, Andrzej, Bednarska, Agnieszka, Jurek, Natalia, Fätkenheuer, Gerd, Malinm, Jakob J., Matthews, Gail, Kelleher, Anthony, Cabrera, Gesalit, Carey, Catherine, Hough, Sally, Virachit, Sophie, Zhong, Amy, Young, Barnaby E., Chia, Po Ying, Lee, Tau Hong, Lin, Ray J., Lye, David, Ong, Sean, Puah, Ser Hon, Yeo, Tsin Wen, Diong, Shiau Hui, Ongko, Juwinda, Hudson, Fleur, Parmar, Mahesh KB, Goodman, Anna, Badrock, Jonathan, Gregory, Adam, Harris, Nicola, Touloumi, Giota, Pantaz, Nikos, Gioukari, Vicky, Lutaakome, Joseph, Kityo, Cissy M., Mugerwa, Henry, Kiweewa, Francis, Osinusi, Anu, Tipple, Craig, Willis, Angela, Peppercorn, Amanda, Watson, Helen, Alexander, Elizabeth, Mogalian, Erik, Lin, Leo, Ding, Xiao, Yan, Li, Girardet, Jean-Luc, Ma, Ji, Hong, Zhi, Adams, Amy, Albert, Sara, Balde, Abby, Baracz, Michelle, Baseler, Beth, Becker, Nancy, Bielica, Mona, Billouin-Frazier, Shere, Cash, Jennifer, Choudhary, Jay, Dolney, Suzanne, Dixon, Mary, Eyler, Carolyn, Frye, Leanna, Galcik, Michael, Gertz, Jensen, Giebeig, Lisa, Gulati, Neelam, Hankinson, Liz, Hissey, Debbie, Hogarty, Debi, Hohn, Matt, Holley, H Preston, Hoopengardner, Lisa, Huber, Lynda, Jankelevich, Shirley, Krauss, Gary, Lake, Eileen, Linton, Jessica, MacDonald, Leah, Manandhar, Meryan, Spinelli-Nadzam, Mary, Oluremi, Charles, Proffitt, Calvin, Rudzinski, Erin, Sandrus, Jen, Schaffhauser, Marylu, Schechner, Adam, Suders, Connie, Gerry, Norman P., Smith, Kenneth, Solomon, Courtney, Kubernac, Amanda, Rashid, Marium, Patel, Bhakti, Kubernac, Robert, Murphy, Joseph, Hoover, Marie L., Brown, Craig, DuChateau, Nadine, Flosi, Adam, Johnson, Les, Treagus, Amy, and Wenner, Christine
- Published
- 2022
- Full Text
- View/download PDF
21. Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV
- Author
-
Bick, Alexander G., Popadin, Konstantin, Thorball, Christian W., Uddin, Md Mesbah, Zanni, Markella V., Yu, Bing, Cavassini, Matthias, Rauch, Andri, Tarr, Philip, Schmid, Patrick, Bernasconi, Enos, Günthard, Huldrych F., Libby, Peter, Boerwinkle, Eric, McLaren, Paul J., Ballantyne, Christie M., Grinspoon, Steven, Natarajan, Pradeep, and Fellay, Jacques
- Published
- 2022
- Full Text
- View/download PDF
22. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV
- Author
-
Bick, Alexander G., Popadin, Konstantin, Thorball, Christian W., Uddin, Md Mesbah, Zanni, Markella V., Yu, Bing, Cavassini, Matthias, Rauch, Andri, Tarr, Philip, Schmid, Patrick, Bernasconi, Enos, Günthard, Huldrych F., Libby, Peter, Boerwinkle, Eric, McLaren, Paul J., Ballantyne, Christie M., Grinspoon, Steven, Natarajan, Pradeep, and Fellay, Jacques
- Published
- 2022
- Full Text
- View/download PDF
23. Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients
- Author
-
Kusejko, Katharina, Chammartin, Frédérique, Smith, Daniel, Odermatt, Marc, Schuhmacher, Julian, Koller, Michael, Günthard, Huldrych F., Briel, Matthias, Bucher, Heiner C., and Speich, Benjamin
- Published
- 2022
- Full Text
- View/download PDF
24. Using viral diversity to identify HIV-1 variants under HLA-dependent selection in a systematic viral genome-wide screen.
- Author
-
Neuner-Jehle, Nadia, Zeeb, Marius, Thorball, Christian W., Fellay, Jacques, Metzner, Karin J., Frischknecht, Paul, Neumann, Kathrin, Leeman, Christine, Rauch, Andri, Stöckle, Marcel, Huber, Michael, Perreau, Matthieu, Bernasconi, Enos, Notter, Julia, Hoffmann, Matthias, Leuzinger, Karoline, Günthard, Huldrych F., Pasin, Chloé, and Kouyos, Roger D.
- Subjects
HLA histocompatibility antigens ,WHOLE genome sequencing ,VIRAL load ,IMMUNE recognition ,VIRAL mutation - Abstract
The pathogenesis of HIV-1 infection is governed by a highly dynamic, time-dependent interaction between the host and the viral genome. In this study, we developed a novel systematic approach to assess the host-virus interaction, using average pairwise viral diversity as a proxy for time since infection, and applied this method to nearly whole viral genome sequences (n = 4,464), human leukocyte antigen (HLA) genotyping data (n = 1,044), and viral RNA load (VL) measurements during the untreated chronic phase (n = 829) of Swiss HIV Cohort Study participants. Our systematic genome-wide screen revealed for 98 HLA/viral-variant pairs a signature of immune-driven selection in the form of an HLA-dependent effect of infection time on the presence of HIV amino acid variants. Of these pairs, 12 were found to have an effect on VL. Furthermore, 28/58 pairs were validated by time-to-event analyses and 48/92 by computational HLA-epitope predictions. Our diversity-based approach allows a powerful and systematic investigation of the interaction between the virus and cellular immunity, revealing a notable subset of such interaction effects. From an evolutionary perspective, these observations underscore the complexity of HLA-mediated selection pressures on the virus that shape viral evolution and pathogenesis. Author summary: The intricate interplay between viruses and the human immune system is reflected in dynamic associations between the viral and the human genomes. These often take the form of escape dynamics, in which the virus acquires mutations that allow it to evade immune recognition. We developed a novel viral diversity-based method to screen for such interactions across the viral genome systematically and applied it to a unique dataset of HIV-1 sequences and human leukocyte antigen (HLA) variants. We could identify time-dependent interactions between 98 pairs of HLA and viral variants. Among these pairs, 12 were associated with the concentration of viral RNA, longitudinal time-to-event analyses confirmed 28, and 48 were consistent with computational predictions of viral peptide binding to HLA molecules. Our results highlight how the highly dynamic interaction between the viral genome and the immune system shapes viral evolution, and our approach offers new opportunities to systematically study such interactions from real-world cross-sectional data. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
- Author
-
Saag, Michael S, Benson, Constance A, Gandhi, Rajesh T, Hoy, Jennifer F, Landovitz, Raphael J, Mugavero, Michael J, Sax, Paul E, Smith, Davey M, Thompson, Melanie A, Buchbinder, Susan P, del Rio, Carlos, Eron, Joseph J, Fätkenheuer, Gerd, Günthard, Huldrych F, Molina, Jean-Michel, Jacobsen, Donna M, and Volberding, Paul A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Public Health ,Immunology ,Health Sciences ,Medical Microbiology ,Sexually Transmitted Infections ,HIV/AIDS ,Prevention ,Clinical Trials and Supportive Activities ,Clinical Research ,Infectious Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Adult ,Advisory Committees ,Anti-Retroviral Agents ,Diagnosis ,Differential ,Fees ,Pharmaceutical ,HIV Infections ,Humans ,Time-to-Treatment ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceAntiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection.ObjectiveTo evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for individuals at risk.Evidence reviewNew evidence collected since the International Antiviral Society-USA 2016 recommendations via monthly PubMed and EMBASE literature searches up to April 2018; data presented at peer-reviewed scientific conferences. A volunteer panel of experts in HIV research and patient care considered these data and updated previous recommendations.FindingsART is recommended for virtually all HIV-infected individuals, as soon as possible after HIV diagnosis. Immediate initiation (eg, rapid start), if clinically appropriate, requires adequate staffing, specialized services, and careful selection of medical therapy. An integrase strand transfer inhibitor (InSTI) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is generally recommended for initial therapy, with unique patient circumstances (eg, concomitant diseases and conditions, potential for pregnancy, cost) guiding the treatment choice. CD4 cell count, HIV RNA level, genotype, and other laboratory tests for general health and co-infections are recommended at specified points before and during ART. If a regimen switch is indicated, treatment history, tolerability, adherence, and drug resistance history should first be assessed; 2 or 3 active drugs are recommended for a new regimen. HIV testing is recommended at least once for anyone who has ever been sexually active and more often for individuals at ongoing risk for infection. Preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and appropriate monitoring is recommended for individuals at risk for HIV.Conclusions and relevanceAdvances in HIV prevention and treatment with antiretroviral drugs continue to improve clinical management and outcomes for individuals at risk for and living with HIV.
- Published
- 2018
26. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials
- Author
-
Hedskog, Charlotte, primary, Spinner, Christoph D., additional, Protzer, Ulrike, additional, Hoffmann, Dieter, additional, Ko, Chunkyu, additional, Gottlieb, Robert L., additional, Askar, Medhat, additional, Roestenberg, Meta, additional, de Vries, Jutte J. C., additional, Carbo, Ellen C., additional, Martin, Ross, additional, Li, Jiani, additional, Han, Dong, additional, Rodriguez, Lauren, additional, Parvangada, Aiyappa, additional, Perry, Jason K., additional, Ferrer, Ricard, additional, Antón, Andrés, additional, Andrés, Cristina, additional, Casares, Vanessa, additional, Günthard, Huldrych F., additional, Huber, Michael, additional, McComsey, Grace A., additional, Sadri, Navid, additional, Aberg, Judith A., additional, van Bakel, Harm, additional, and Porter, Danielle P., additional
- Published
- 2024
- Full Text
- View/download PDF
27. Reconciling founder variant multiplicity of HIV-1 infection with the rate of CD4+decline
- Author
-
Baxter, James, primary, Arenas, Ch. Julián Villabona, additional, Thompson, Robin N., additional, Hué, Stéphane, additional, Regoes, Roland R., additional, Kouyos, Roger D., additional, Günthard, Huldrych F., additional, Albert, Jan, additional, Brown, Andrew Leigh, additional, and Atkins, Katherine E., additional
- Published
- 2024
- Full Text
- View/download PDF
28. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
- Author
-
Abela, Irene A., primary, Schwarzmüller, Magdalena, additional, Ulyte, Agne, additional, Radtke, Thomas, additional, Haile, Sarah R., additional, Ammann, Priska, additional, Raineri, Alessia, additional, Rueegg, Sonja, additional, Epp, Selina, additional, Berger, Christoph, additional, Böni, Jürg, additional, Manrique, Amapola, additional, Audigé, Annette, additional, Huber, Michael, additional, Schreiber, Peter W., additional, Scheier, Thomas, additional, Fehr, Jan, additional, Weber, Jacqueline, additional, Rusert, Peter, additional, Günthard, Huldrych F., additional, Kouyos, Roger D., additional, Puhan, Milo A., additional, Kriemler, Susi, additional, Trkola, Alexandra, additional, and Pasin, Chloé, additional
- Published
- 2024
- Full Text
- View/download PDF
29. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
- Author
-
Bansi-Matharu, Loveleen, Phillips, Andrew, Oprea, Cristiana, Grabmeier-Pfistershammer, Katharina, Günthard, Huldrych F, De Wit, Stephane, Guaraldi, Giovanni, Vehreschild, Jorg J, Wit, Ferdinand, Law, Matthew, Wasmuth, Jan-Christian, Chkhartishvili, Nikoloz, d'Arminio Monforte, Antonella, Fontas, Eric, Vesterbacka, Jan, Miro, Jose M, Castagna, Antonella, Stephan, Christoph, Llibre, Josep M, Neesgaard, Bastian, Greenberg, Lauren, Smith, Colette, Kirk, Ole, Duvivier, Claudine, Dragovic, Gordana, Lundgren, Jens, Dedes, Nikos, Knudsen, Andreas, Gallant, Joel, Vannappagari, Vani, Peters, Lars, Elbirt, Daniel, Sarcletti, Mario, Braun, Dominique L, Necsoi, Coca, Mussini, Cristina, Muccini, Camilla, Bolokadze, Natalie, Hoy, Jennifer, Mocroft, Amanda, and Ryom, Lene
- Published
- 2021
- Full Text
- View/download PDF
30. Cohort Profile: The Zurich Primary HIV Infection Study
- Author
-
Freind, Matt C., primary, Tallón de Lara, Carmen, additional, Kouyos, Roger D., additional, Wimmersberger, David, additional, Kuster, Hebert, additional, Aceto, Leonardo, additional, Kovari, Helen, additional, Flepp, Markus, additional, Schibli, Adrian, additional, Hampel, Benjamin, additional, Grube, Christina, additional, Braun, Dominique L., additional, and Günthard, Huldrych F., additional
- Published
- 2024
- Full Text
- View/download PDF
31. Phenotypic and genotypic characterization of Neisseria gonorrhoeae isolates among individuals at high risk for sexually transmitted diseases in Zurich, Switzerland
- Author
-
Jünger, Christian, primary, Imkamp, Frank, additional, Balakrishna, Suraj, additional, Gysin, Marina, additional, Haldimann, Klara, additional, Brugger, Silvio D, additional, Scheier, Thomas C, additional, Hampel, Benjamin, additional, Hobbie, Sven N, additional, Günthard, Huldrych F, additional, and Braun, Dominique L, additional
- Published
- 2024
- Full Text
- View/download PDF
32. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland
- Author
-
Thoueille, Paul, primary, Saldanha, Susana Alves, additional, Schaller, Fabian, additional, Choong, Eva, additional, Munting, Aline, additional, Cavassini, Matthias, additional, Braun, Dominique, additional, Günthard, Huldrych F., additional, Kusejko, Katharina, additional, Surial, Bernard, additional, Furrer, Hansjakob, additional, Rauch, Andri, additional, Rougemont, Mathieu, additional, Ustero, Pilar, additional, Calmy, Alexandra, additional, Stöckle, Marcel, additional, Marzolini, Catia, additional, Di Benedetto, Caroline, additional, Bernasconi, Enos, additional, Schmid, Patrick, additional, Piso, Rein Jan, additional, Andre, Pascal, additional, Girardin, François R., additional, Guidi, Monia, additional, Buclin, Thierry, additional, and Decosterd, Laurent A., additional
- Published
- 2024
- Full Text
- View/download PDF
33. Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection
- Author
-
Hoenigl, Martin, Braun, Dominique L, Kouyos, Roger, Günthard, Huldrych F, and Little, Susan J
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Good Health and Well Being ,Acute Disease ,Acute Retroviral Syndrome ,Adolescent ,Adult ,Aged ,Anti-Retroviral Agents ,Antiretroviral Therapy ,Highly Active ,Disease Progression ,Ethnicity ,Female ,Follow-Up Studies ,Humans ,Male ,Middle Aged ,Retrospective Studies ,Risk Factors ,Surveys and Questionnaires ,Viral Load ,Young Adult ,Clinical Sciences ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Published
- 2017
34. 2017 Update of the Drug Resistance Mutations in HIV-1.
- Author
-
Wensing, Annemarie M, Calvez, Vincent, Günthard, Huldrych F, Johnson, Victoria A, Paredes, Roger, Pillay, Deenan, Shafer, Robert W, and Richman, Douglas D
- Subjects
Humans ,HIV-1 ,Drug Resistance ,Viral ,Mutation ,Societies ,Scientific ,United States ,Drug Resistance ,Viral ,Societies ,Scientific - Abstract
The 2017 edition of the IAS-USA drug resistance mutations list updates the figures last published in November 2015. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The figures are designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs and, therefore, in making clinical decisions regarding antiretroviral therapy.
- Published
- 2016
35. Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics
- Author
-
Kusejko, Katharina, Tschumi, Nadine, Chaudron, Sandra E., Nguyen, Huyen, Battegay, Manuel, Bernasconi, Enos, Böni, Jürg, Huber, Michael, Calmy, Alexandra, Cavassini, Matthias, Egle, Alexander, Grabmeier-Pfistershammer, Katharina, Haas, Bernhard, Hirsch, Hans, Klimkait, Thomas, Öllinger, Angela, Perreau, Matthieu, Ramette, Alban, Flury, Baharak Babouee, Sarcletti, Mario, Scherrer, Alexandra, Schmid, Patrick, Yerly, Sabine, Zangerle, Robert, Günthard, Huldrych F., and Kouyos, Roger D.
- Published
- 2022
- Full Text
- View/download PDF
36. Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV.
- Author
-
Roen, Ashley O, Peters, Lars, Wandeler, Gilles, van der Valk, Marc, Zangerle, Robert, Günthard, Huldrych F, Wit, Ferdinand, Mussini, Cristina, Wit, Stéphane De, Monforte, Antonella d'Arminio, Vehreschild, Jörg Janne, Castagna, Antonella, Jaschinski, Nadine, Vannappagari, Vani, Chen, Linda, Tallada, Joan, C'mar, John, Mocroft, Amanda, and Ryom, Lene
- Subjects
LIVER enzymes ,HIV-positive persons ,NON-nucleoside reverse transcriptase inhibitors ,POISSON regression ,ANTIRETROVIRAL agents - Abstract
Background While use of some older antiretroviral drugs (ARVs) is associated with chronic liver enzyme elevation (cLEE), the impact of newer ARVs remains unknown. Methods People with HIV enrolled in the RESPOND cohort who started an ARV after January 1, 2012 were included (baseline). The primary outcome was first cLEE individuals were censored at first of cLEE, last visit, death, or December 31, 2021. Incidence rates (IRs; events/1000 person-years) were calculated for each ARV overall and by ARV exposure (6–12 months, 1–2 years, and 2+ years). Poisson regression was used to estimate the incidence rate ratio (IRR) of cLEE and its association with individual ARVs and ARV class. Results Of 17 106 individuals included contributing 87 924 person-years of follow-up, 1932 (11.3%) experienced cLEE (incidence rate [IR], 22.0; 95% CI, 21.0–23.0). There was no evidence of a cumulative ARV effect on cLEE incidence, (6–12 months: IR, 45.8; 95% CI, 41.4–50.19; 1–2 years: IR, 34.3; 95% CI, 31.5–37.4; and 2+ years: IR, 18.5; 95% CI, 17.4–19.7). Any use (vs no prior use) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) as a class and tenofovir disoproxil fumarate (TDF) was independently associated with an increased IRR of cLEE, and any use of darunavir (DRV) was associated with a decreased risk of cLEE. Conclusions cLEE is common and more frequent during the first year after initiating new ARVs. With a >5-year median follow-up, we found no short-term liver safety concerns with the use of INSTIs. Use of NNRTIs and TDF was associated with an increased cLEE risk, while DRV was associated with lower risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV.
- Author
-
Thoueille, Paul, Saldanha, Susana Alves, Schaller, Fabian, Choong, Eva, Veuve, François, Munting, Aline, Cavassini, Matthias, Braun, Dominique, Günthard, Huldrych F., Duran Ramirez, Jessy J., Surial, Bernard, Furrer, Hansjakob, Rauch, Andri, Ustero, Pilar, Calmy, Alexandra, Stöckle, Marcel, Di Benedetto, Caroline, Bernasconi, Enos, Schmid, Patrick, and Marzolini, Catia
- Subjects
ORAL drug administration ,INTRAMUSCULAR injections ,HIV-positive persons ,PHARMACOKINETICS ,BODY mass index - Abstract
Long‐acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings. The present population pharmacokinetic analysis aims to build real‐world reference percentile curves of cabotegravir concentrations, accounting for patient‐related factors that may affect cabotegravir exposure. The second objective is to simulate whether dosing interval adjustments of cabotegravir could be considered in specific subpopulations. Overall, 238 PWH contributed to 1,038 cabotegravir levels (186 during the initial oral administration phase and 852 after intramuscular injection). Cabotegravir pharmacokinetics was best described using a one‐compartment model with distinct first order‐absorption for oral and intramuscular administrations, and identical volume and clearance. Our model showed almost 40% faster absorption and 30% higher clearance than previously reported, resulting in a time to steady‐state of 8 months and an elimination half‐life of 4.6 weeks for long‐acting cabotegravir. Sex and body mass index significantly influenced absorption, and bodyweight affected clearance. Model‐based simulations showed that cabotegravir trough concentrations in females were 25% lower 4 weeks after the intramuscular loading dose, but 42% higher during the late maintenance phase. Finally, simulations indicated that in females, despite significantly higher cabotegravir concentrations, longer intervals between injections may not consistently ensure levels above the 4‐fold protein‐adjusted 90% inhibitory target concentration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Characterization and Determinants of Long-Term Immune Recovery Under Suppressive Antiretroviral Therapy.
- Author
-
Turk, Teja, Labarile, Marco, Braun, Dominique L., Rauch, Andri, Stöckle, Marcel, Cavassini, Matthias, Hoffmann, Matthias, Calmy, Alexandra, Bernasconi, Enos, Notter, Julia, Pasin, Chloé, Günthard, Huldrych F., and Kouyos, Roger D.
- Published
- 2024
- Full Text
- View/download PDF
39. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel
- Author
-
Günthard, Huldrych F, Saag, Michael S, Benson, Constance A, del Rio, Carlos, Eron, Joseph J, Gallant, Joel E, Hoy, Jennifer F, Mugavero, Michael J, Sax, Paul E, Thompson, Melanie A, Gandhi, Rajesh T, Landovitz, Raphael J, Smith, Davey M, Jacobsen, Donna M, and Volberding, Paul A
- Subjects
Biomedical and Clinical Sciences ,Public Health ,Clinical Sciences ,Immunology ,Health Sciences ,Medical Microbiology ,HIV/AIDS ,Sexually Transmitted Infections ,Patient Safety ,Infectious Diseases ,Prevention ,Clinical Trials and Supportive Activities ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,AIDS-Related Opportunistic Infections ,Adolescent ,Adult ,Aged ,Anti-Retroviral Agents ,CD4 Lymphocyte Count ,Drug Therapy ,Combination ,Female ,HIV Infections ,HIV-1 ,Humans ,Male ,Middle Aged ,Post-Exposure Prophylaxis ,Pre-Exposure Prophylaxis ,Pregnancy ,Prognosis ,Treatment Failure ,Viral Load ,Viremia ,Young Adult ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceNew data and therapeutic options warrant updated recommendations for the use of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults.ObjectiveTo provide updated recommendations for the use of antiretroviral therapy in adults (aged ≥18 years) with established HIV infection, including when to start treatment, initial regimens, and changing regimens, along with recommendations for using ARVs for preventing HIV among those at risk, including preexposure and postexposure prophylaxis.Evidence reviewA panel of experts in HIV research and patient care convened by the International Antiviral Society-USA reviewed data published in peer-reviewed journals, presented by regulatory agencies, or presented as conference abstracts at peer-reviewed scientific conferences since the 2014 report, for new data or evidence that would change previous recommendations or their ratings. Comprehensive literature searches were conducted in the PubMed and EMBASE databases through April 2016. Recommendations were by consensus, and each recommendation was rated by strength and quality of the evidence.FindingsNewer data support the widely accepted recommendation that antiretroviral therapy should be started in all individuals with HIV infection with detectable viremia regardless of CD4 cell count. Recommended optimal initial regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (InSTI). Other effective regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inhibitors with 2 NRTIs. Recommendations for special populations and in the settings of opportunistic infections and concomitant conditions are provided. Reasons for switching therapy include convenience, tolerability, simplification, anticipation of potential new drug interactions, pregnancy or plans for pregnancy, elimination of food restrictions, virologic failure, or drug toxicities. Laboratory assessments are recommended before treatment, and monitoring during treatment is recommended to assess response, adverse effects, and adherence. Approaches are recommended to improve linkage to and retention in care are provided. Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use as preexposure prophylaxis to prevent HIV infection in persons at high risk. When indicated, postexposure prophylaxis should be started as soon as possible after exposure.Conclusions and relevanceAntiretroviral agents remain the cornerstone of HIV treatment and prevention. All HIV-infected individuals with detectable plasma virus should receive treatment with recommended initial regimens consisting of an InSTI plus 2 NRTIs. Preexposure prophylaxis should be considered as part of an HIV prevention strategy for at-risk individuals. When used effectively, currently available ARVs can sustain HIV suppression and can prevent new HIV infection. With these treatment regimens, survival rates among HIV-infected adults who are retained in care can approach those of uninfected adults.
- Published
- 2016
40. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes
- Author
-
Mocroft, Amanda, primary, Pelchen-Matthews, Annegret, additional, Hoy, Jennifer, additional, Llibre, Josep M., additional, Neesgaard, Bastian, additional, Jaschinski, Nadine, additional, Domingo, Pere, additional, Rasmussen, Line Dahlerup, additional, Günthard, Huldrych F., additional, Surial, Bernard, additional, Öllinger, Angela, additional, Knappik, Michael, additional, De Wit, Stephan, additional, Wit, Ferdinand, additional, Mussini, Cristina, additional, Vehreschild, Joerg, additional, Monforte, Antonella D’Arminio, additional, Sonnerborg, Anders, additional, Castagna, Antonella, additional, Anne, Alain Volny, additional, Vannappagari, Vani, additional, Cohen, Cal, additional, Greaves, Wayne, additional, Wasmuth, Jan C., additional, Spagnuolo, Vincenzo, additional, and Ryom, Lene, additional
- Published
- 2023
- Full Text
- View/download PDF
41. T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C
- Author
-
Caraballo Cortés, Kamila, primary, Osuch, Sylwia, additional, Perlejewski, Karol, additional, Radkowski, Marek, additional, Janiak, Maciej, additional, Berak, Hanna, additional, Rauch, Andri, additional, Fehr, Jan S, additional, Hoffmann, Matthias, additional, Günthard, Huldrych F, additional, and Metzner, Karin J, additional
- Published
- 2023
- Full Text
- View/download PDF
42. Bridging the Gap: identifying factors impacting mRNA SARS-CoV-2 vaccine booster response in people living with HIV-1
- Author
-
Chammartin, Frédérique, primary, Griessbach, Alexandra, additional, Kusejko, Katharina, additional, Audigé, Annette, additional, Epp, Selina, additional, Stoeckle, Marcel P., additional, Eichenberger, Anna L., additional, Amstutz, Alain, additional, Schoenenberger, Christof M, additional, Hasse, Barbara, additional, Braun, Dominique L., additional, Rauch, Andri, additional, Trkola, Alexandra, additional, Briel, Matthias, additional, Bucher, Heiner C, additional, Günthard, Huldrych F., additional, Speich, Benjamin, additional, and Abela, Irene A., additional
- Published
- 2023
- Full Text
- View/download PDF
43. 2015 Update of the Drug Resistance Mutations in HIV-1.
- Author
-
Wensing, Annemarie M, Calvez, Vincent, Günthard, Huldrych F, Johnson, Victoria A, Paredes, Roger, Pillay, Deenan, Shafer, Robert W, and Richman, Douglas D
- Subjects
Humans ,HIV-1 ,Anti-HIV Agents ,Drug Resistance ,Viral ,Mutation ,United States ,Drug Resistance ,Viral - Abstract
The 2015 edition of the IAS-USA drug resistance mutations list updates the figures last published in July 2014. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The figures are designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs and, therefore, in making clinical decisions regarding antiretroviral therapy.
- Published
- 2015
44. Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization
- Author
-
Friedrich, Nikolas, Stiegeler, Emanuel, Glögl, Matthias, Lemmin, Thomas, Hansen, Simon, Kadelka, Claus, Wu, Yufan, Ernst, Patrick, Maliqi, Liridona, Foulkes, Caio, Morin, Mylène, Eroglu, Mustafa, Liechti, Thomas, Ivan, Branislav, Reinberg, Thomas, Schaefer, Jonas V., Karakus, Umut, Ursprung, Stephan, Mann, Axel, Rusert, Peter, Kouyos, Roger D., Robinson, John A., Günthard, Huldrych F., Plückthun, Andreas, and Trkola, Alexandra
- Published
- 2021
- Full Text
- View/download PDF
45. Do we cause false positives? An experimental series on droplet or airborne SARS-CoV-2 contamination of sampling tubes during swab collection in a test center
- Author
-
Scheier, Thomas, Shah, Cyril, Huber, Michael, Sax, Hugo, Hasse, Barbara, Günthard, Huldrych F., Trkola, Alexandra, and Schreiber, Peter W.
- Published
- 2021
- Full Text
- View/download PDF
46. Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
- Author
-
Abela, Irene A., Pasin, Chloé, Schwarzmüller, Magdalena, Epp, Selina, Sickmann, Michèle E., Schanz, Merle M., Rusert, Peter, Weber, Jacqueline, Schmutz, Stefan, Audigé, Annette, Maliqi, Liridona, Hunziker, Annika, Hesselman, Maria C., Niklaus, Cyrille R., Gottschalk, Jochen, Schindler, Eméry, Wepf, Alexander, Karrer, Urs, Wolfensberger, Aline, Rampini, Silvana K., Meyer Sauteur, Patrick M., Berger, Christoph, Huber, Michael, Böni, Jürg, Braun, Dominique L., Marconato, Maddalena, Manz, Markus G., Frey, Beat M., Günthard, Huldrych F., Kouyos, Roger D., and Trkola, Alexandra
- Published
- 2021
- Full Text
- View/download PDF
47. Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals
- Author
-
Moldt, Brian, Günthard, Huldrych F., Workowski, Kimberly A., Little, Susan J., Eron, Joseph J., Overton, Edgar T., Lehmann, Clara, Rokx, Casper, Kozal, Michael J., Gandhi, Rajesh T., Braun, Dominique L., Parvangada, Aiyappa, Li, Jiani, Martin, Ross, Selzer, Lisa, Cox, Stephanie, Margot, Nicolas, Liu, Hui, Slamowitz, Debbie, Makadzange, Tariro, Collins, Sean E., Geleziunas, Romas, and Callebaut, Christian
- Published
- 2022
- Full Text
- View/download PDF
48. Simultaneously estimating evolutionary history and repeated traits phylogenetic signal: applications to viral and host phenotypic evolution
- Author
-
Vrancken, Bram, Lemey, Philippe, Rambaut, Andrew, Bedford, Trevor, Longdon, Ben, Günthard, Huldrych F, and Suchard, Marc A
- Subjects
Genetics ,Infectious Diseases ,HIV/AIDS ,Infection ,adaptation ,Bayesian phylogenetics ,comparative approach ,virulence ,virus evolution ,Environmental Science and Management ,Ecology ,Evolutionary Biology - Abstract
Phylogenetic signal quantifies the degree to which resemblance in continuously-valued traits reflects phylogenetic relatedness. Measures of phylogenetic signal are widely used in ecological and evolutionary research, and are recently gaining traction in viral evolutionary studies. Standard estimators of phylogenetic signal frequently condition on data summary statistics of the repeated trait observations and fixed phylogenetics trees, resulting in information loss and potential bias. To incorporate the observation process and phylogenetic uncertainty in a model-based approach, we develop a novel Bayesian inference method to simultaneously estimate the evolutionary history and phylogenetic signal from molecular sequence data and repeated multivariate traits. Our approach builds upon a phylogenetic diffusion framework that model continuous trait evolution as a Brownian motion process and incorporates Pagel's λ transformation parameter to estimate dependence among traits. We provide a computationally efficient inference implementation in the BEAST software package. We evaluate the synthetic performance of the Bayesian estimator of phylogenetic signal against standard estimators, and demonstrate the use of our coherent framework to address several virus-host evolutionary questions, including virulence heritability for HIV, antigenic evolution in influenza and HIV, and Drosophila sensitivity to sigma virus infection. Finally, we discuss model extensions that will make useful contributions to our flexible framework for simultaneously studying sequence and trait evolution.
- Published
- 2015
49. Hepatitis delta infection among persons living with HIV in Europe
- Author
-
Béguelin, Charles, Atkinson, Andrew, Boyd, Anders, Falconer, Karolin, Kirkby, Nikolai, Suter Riniker, Franziska, Günthard, Huldrych F., Rockstroh, Jürgen Kurt, Mocroft, Amanda, Rauch, Andri, Peters, Lars, Wandeler, Gilles, for EuroSIDA and SHCS, Miró Meda, José M., Infectious diseases, and AII - Infectious diseases
- Subjects
PLWH ,Hepatology ,HIV (Viruses) ,prevalence ,HIV ,Virus de l'hepatitis delta ,Hepatitis B ,Càncer de fetge ,Europe ,Hepatitis vírica ,Hepatitis Delta ,VIH (Virus) ,Viral hepatitis ,HIV-positive persons ,HCC ,Persones seropositives ,Europa ,Liver cancer ,Delta-associated agent - Abstract
Background and Aims: A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe. We analysed data from a large HIV cohort collaboration to characterize HDV epidemiological trends across Europe, as well as its impact on clinical outcomes. Methods: All PLWH with a positive hepatitis B surface antigen (HBsAg) in the Swiss HIV Cohort Study and EuroSIDA between 1988 and 2019 were tested for anti-HDV antibodies and, if positive, for HDV RNA. Demographic and clinical characteristics at initiation of antiretroviral therapy were compared between HDV-positive and HDV-negative individuals using descriptive statistics. The associations between HDV infection and overall mortality, liver-related mortality as well as hepatocellular carcinoma (HCC) were assessed using cumulative incidence plots and cause-specific multivariable Cox regression. Results: Of 2793 HBsAg-positive participants, 1556 (56%) had stored serum available and were included. The prevalence of HDV coinfection was 15.2% (237/1556, 95% confidence interval [CI]: 13.5%?17.1%) and 66% (132/200) of HDV-positive individuals had active HDV replication. Among persons who inject drugs (PWID), the prevalence of HDV coinfection was 50.5% (182/360, 95% CI: 45.3%?55.7%), with similar estimates across Europe, compared to 4.7% (52/1109, 95% CI: 3.5%?5.9%) among other participants. During a median follow-up of 10.8 years (interquartile range 5.6?17.8), 82 (34.6%) HDV-positive and 265 (20.1%) HDV-negative individuals died. 41.5% (34/82) of deaths were liver-related in HDV-positive individuals compared to 17.7% (47/265) in HDV-negative individuals. HDV infection was associated with overall mortality (adjusted hazard ratio 1.6; 95% CI 1.2?2.1), liver-related death (2.9, 1.6?5.0) and HCC (6.3, 2.5?16.0). Conclusion: We found a very high prevalence of hepatitis delta among PWID across Europe. Among PLWH who do not inject drugs, the prevalence was similar to that reported from populations without HIV. HDV coinfection was associated with liver-related mortality and HCC incidence.
- Published
- 2023
50. 2014 Update of the drug resistance mutations in HIV-1.
- Author
-
Wensing, Annemarie M, Calvez, Vincent, Günthard, Huldrych F, Johnson, Victoria A, Paredes, Roger, Pillay, Deenan, Shafer, Robert W, and Richman, Douglas D
- Subjects
Humans ,HIV-1 ,HIV Infections ,Anti-HIV Agents ,Drug Resistance ,Viral ,Mutation ,Missense ,Point Mutation ,Drug Resistance ,Viral ,Mutation ,Missense - Abstract
This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.